title: [Future molecules in heart failure].
abstract: TODAY: The management of heart failure (HF) has considerably progressed over the last two decades. Treatment today relies on prevention and treatment of congestion (limited salt intake, diuretics, converting enzyme inhibitors) and limiting neurohormone stimulation (converting enzyme inhibitors +/- aldactone, beta-blockers). IN THE YEARS TO COME: Based on new concepts, several therapeutic strategies are interesting: blocking over vasoconstrictor systems which have not been taking into account; stimulation of vasodilator and natriuretic systems; modulation of cardiac remodelling; modulation of the immune and inflammatory systems; modification in intrinsic contractility; prevention of rhythm disorders. Among these differing strategies and molecules, it is not easy to predict those that will change the HF prognosis. In any event, their efficacy and safety remain to be demonstrated with large cohort randomised studies. THE PRINCIPLES: To reduce the number of drugs administered, two options appear particularly interesting: measurement of hormone levels (BNP) in order to adjust treatment and administration of molecules with greatest efficacy and safety profiles; limit cardiac remodelling by using new imaging techniques to detect it more precisely and select the molecule(s) exerting the required effect. To target the new molecules better, patients should be classified according to their etiology, stage and progressive profile of their disease, cardiac remodelling, expression of principle endocrine systems and pro-inflammatory cytokines, expression of inflammatory and immune systems and inherent genetic characteristics and response to treatment. This would permit the adaptation of treatment to each individual patient with heart failure.
authors.affiliation: Fédération des services de Cardiologie et service de Médecíne Nucléaire, INSERM U400 et Centre de Recherches Chirurgicales, Hôpital Henri Mondor, Créteil. luc.hittinger@hmn.ap-hop-paris.fr
authors.forename: L
authors.initials: L
authors.lastname: Hittinger
authors.forename: M E
authors.initials: ME
authors.lastname: Lopes
authors.forename: J Y
authors.initials: JY
authors.lastname: Tabet
authors.forename: P
authors.initials: P
authors.lastname: Le Corvoisier
authors.forename: J B
authors.initials: JB
authors.lastname: Su
authors.forename: A M
authors.initials: AM
authors.lastname: Duval-Moulin
authors.forename: F
authors.initials: F
authors.lastname: Jan
authors.forename: P
authors.initials: P
authors.lastname: Merlet
authors.forename: J L
authors.initials: JL
authors.lastname: Dubois-Randé
mesh_terms: D005544:Forecasting; D006333:Heart Failure / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D006801:Humans